Erythroid Cells-targeting Adenovirus Vector Construction Service
Creative Biolabs' long-term efforts have allowed us to build an advanced and mature vector construction platform. We launched the erythroid cells-targeting adenovirus vector construction service on our adenoviral vector (AV) construction platform to accurately locate erythroid cells by optimizing and modifying traditional AV. We will construct the appropriate gene delivery vector for your experiment according to your different needs. No matter what difficulties you have encountered in the relevant research work, you can contact us to get your customized service.
Erythroid Cells-targeting Gene Therapy
In mature red blood cells, a number of metabolic pathways such as glycolysis provide the body with most of the energy source. The main cause of erythroid hereditary diseases is genetic mutations in enzymes associated with metabolic pathways. The lack of metabolic enzymes or loss of function destroys the energy balance of red blood cells and causes various diseases. The oxygen affinity of hemoglobin, and the ability to transport to other tissues are also affected. Although there is a comprehensive and detailed understanding of the molecular mechanisms of these metabolic pathways, the level of treatment for erythroid gene-deficient diseases remains immature.
A relatively effective treatment is traditional bone marrow transplantation, which can produce donor-derived functional hematopoietic cells in a patient's body and can treat most related diseases. However, bone marrow transplantation is not only demanding, but also has a high risk of various complications after transplantation. Nowadays, emerging gene therapy technologies are clearly a safer option in the future. By stabilizing the corrected genes into autologous hematopoietic stem cells (HSCs) and their offspring, this technology not only overcome the limitation of human leukocyte antigen (HLA)-compatible donor availability, so it can be applied to every patient, but also reduce the risk of graft versus host disease (GvHD) and consequently block the need for post-transplant immunosuppression.
Adenovirus Vector for Gene Therapy
Adenoviruses are widely distributed in nature. Human adenoviruses are representative of mammalian adenoviruses. There are more than 50 serotypes with different tissue tropisms, providing a rich tool library for gene therapy for different targets. Adenoviruses typically enter the cell by endocytosis, and the viral genome is transferred to the nucleus for expression with the help of dynein and nucleoporin. Adenoviral vectors have been widely used in clinical trials of human gene therapy due to their stable gene delivery functions. Adenovirus can introduce larger DNA or even multiple DNA fragments into host cells, and because of its stable and intuitive genomic structure, it is excellent in safety and genetic manipulation, so it will be one of the most promising viral vectors in the future gene therapy field. The replication-deficient adenovirus currently constructed by the long terminal repeat promoter of Rous sarcoma virus has successfully achieved stable expression of erythropoietin (EPO) in mice, indicating that adenovirus-mediated gene therapy for blood cell-related diseases has a bright future.
Creative Biolabs can optimize the construction of adenoviral vectors by various chemical modification methods and specific molecules, reducing its immunogenicity and increasing the tissue targeting of the vector. Our erythroid cells-targeting adenovirus vector construction service can build a safe and efficient adenoviral vector to meet your needs for erythroid cell genetic research. If you have any questions or have any difficulties, please contact us by email or send us an inquiry to find a complete solution.
